Baidu
map

Cancer Discov:三阴性乳腺癌新疗法——BBOX1抑制剂

2020-08-02 黎元 医药魔方

与其它呈激素受体或HER2阳性的癌症不同,三阴性乳腺癌几乎无靶向疗法可用,只能依靠手术、化疗和放疗来进行治疗,但效果不如靶向治疗,会伤害健康组织。研究发现BBOX1可以作为三阴性乳腺癌的可行治疗靶点。

三阴性乳腺癌(TNBC)因雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)均为阴性表达得名,虽然仅占所有乳腺癌的15%-20%,但却是其中最致命的一种,五年生存率为77%,其它类型的乳腺癌的五年生存率为93%。

与其它呈激素受体或HER2阳性的癌症不同,三阴性乳腺癌几乎无靶向疗法可用,患者只能依靠手术、化疗和放疗来进行治疗,这些疗法的效果不如靶向治疗,而且会伤害健康组织。

发表在Cancer Discovery杂志上的一项新研究中,德克萨斯大学西南医学中心(UTSW)的张青博士团队发现BBOX1可以作为三阴性乳腺癌的可行治疗靶点。这可能为部分缺乏有效治疗选择,且往往面临不良预后的患者带来希望。

张青博士是UTSW病理学系的副教授。为了寻找三阴性乳腺癌的可行药物靶点,他的研究团队将重点放在了α-酮戊二酸(2-oxoglutarate, 2OG)依赖性酶上,这是一个包含70种酶的酶家族,其中一些酶在细胞中起着氧传感器的作用。为了确定这些酶在三阴性乳腺癌中的作用,研究人员使用一个小干扰RNA(可关闭特定基因表达的遗传片段)库,分别关闭了不同三阴性乳腺癌和健康人群乳腺细胞系中α-酮戊二酸依赖酶家族的每个成员。

研究重点迅速缩小到一个特定酶——BBOX1(gamma-butyrobetaine hydroxylase 1)上,BBOX1可促进肉碱的细胞合成,肉碱在能量代谢中起着关键作用。当负责产生BBOX1的基因被关闭时,对健康的乳腺细胞没有任何作用,但三阴性乳腺癌细胞停止分裂并最终死亡。

BBOX1以酶依赖性方式促进三阴性乳腺癌细胞生长。同时,编码BBOX1基因的过表达会导致三阴性乳腺癌细胞株大量增殖。进一步的研究表明,引起这种作用的并不是肉碱(BBOX1酶的最终产物)。BBOX1本身似乎是三阴性乳腺癌细胞存活和生长的关键。

为了研究BBOX1如何发挥这种作用,研究人员搜寻了BBOX1在细胞中与哪些蛋白质相互作用。实验结果表明,BBOX1能专一结合一种蛋白质IP3R3,此前的研究表明IP3R3与其它恶性肿瘤有关。IP3R3在帮助线粒体从糖中获取能量中非常重要。BBOX1能与IP3R3结合并阻止其降解,从而为三阴性乳腺癌细胞提供了生长所需的能量。

另一方面,清除BBOX1可能会阻止三阴性乳腺癌肿瘤的发展,这一结论在小鼠实验中得到了证明。向小鼠注射经过修饰后直接关闭BBOX1基因的三阴性乳腺癌细胞,阻止了原发肿瘤的生长。在第二种方法中,研究人员将肿瘤细胞注射到小鼠体内,不影响癌细胞的生长直到变为较大的肿瘤。然后,向小鼠喂食强力霉素(一种抗生素)来关闭BBOX1基因。研究人员发现这些肿瘤停止生长并缩小。

随后研究团队向小鼠中添加抑制BBOX1的药物来复制以上结果。结果显示这些药物能够有效对抗肿瘤,对正常的乳腺组织或实验动物整体没有负面影响,没有可检测到的毒性。

实验所用的BBOX1抑制剂中的两种(C-2124和AR692B)仍然在研,另一种药物米屈肼(Mildronate)在欧洲的一些国家已被获批用于增加组织中的氧气来治疗冠状动脉疾病。张青博士认为包括Mildronate在内的BBOX1抑制剂最终可能成为三阴性乳腺癌患者一直在等待的靶向疗法。

“目前三阴性乳腺癌患者的治疗选择有限,导致了较差的临床效果。我们认为BBOX1抑制剂可能是治疗三阴性乳腺癌的强大武器。”张青博士补充道。

原始出处:

Chengheng Liao 1, Yang Zhang 2, Cheng Fan 3, et al.Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.Cancer Discov. 2020 Jul 20;CD-20-0288. doi: 10.1158/2159-8290.CD-20-0288.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2021-12-25 ms5000001219560845

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-08-05 ms3000000449926787

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-08-04 xlysu
  7. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-08-04 kcb074
  8. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-08-04 yankaienglish
  9. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-08-02 1477256fm79(暂无昵称)

    学习到了,三阴性乳腺癌是一个难攻的课题。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1084254, encodeId=8ceb1084254b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33256424173, createdName=ms5000001219560845, createdTime=Sat Dec 25 21:51:02 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Fri Aug 21 21:29:43 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013436, encodeId=b1482013436d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jul 02 19:29:43 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852451, encodeId=ca9718524515f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jun 24 23:29:43 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806327, encodeId=dbdb80632e40, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Aug 05 15:17:39 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458782, encodeId=9a731458e82dd, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554584, encodeId=4bc515545840e, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587899, encodeId=46c5158e899ea, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Tue Aug 04 01:29:43 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805728, encodeId=f03c805e285a, content=学习到了,三阴性乳腺癌是一个难攻的课题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc835217625, createdName=1477256fm79(暂无昵称), createdTime=Sun Aug 02 11:50:18 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805725, encodeId=3402805e25a2, content=<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>米屈肼有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19821, encryptionId=33771982175, topicName=三阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Aug 02 10:50:06 CST 2020, time=2020-08-02, status=1, ipAttribution=)]
    2020-08-02 lovetcm

    #三阴性乳腺癌#米屈肼有用?

    0

相关资讯

Science Advances:给毛囊补充一次“营养”细胞,重塑90%脱发区域

对于当代青年人来说,最难受的莫过于年纪轻轻就“没”了头发。据统计,在中国,大约2.5亿人深受脱发困扰,平均六个人当中就有一个人存在脱发症状,并且脱发现象日趋低龄化。

Lancet Oncology:人体内有那么多微生物,它们对癌症的发生和治疗有哪些影响?

人体微生物组与我们共同进化、共同生存,也与我们的健康有着复杂联系。比如我们常说的肠道菌群,其多样性和构成情况,对每个人来说都是独特的健康相关特征。今年探索了很多人体不同组织内的微生物与癌症的关联。

盘点:近期鼻炎治疗进展

【1】Am J Rhinol Allergy:屋尘螨舌下免疫治疗在儿童和成年人过敏性鼻炎治疗中的比较

盘点:近期听力损失治疗进展

【1】Int J Pediatr Otorhinolaryngol:单边耳聋儿童的治疗挑战和临床特征

英国专家将新冠疾病分成6组症状群,或有助针对性治疗

据欧联网援引欧联社综合报道,近日,英国科学家将新冠病毒疾病分为了6种不同的“类型”,这可能有助于新冠病毒感染的治疗。研究人员表示,这可以帮助医生更好地针对具体病人进行酌情治疗,

盘点:近期前列腺癌治疗进展

【1】Eur Urol:无化疗转移去势抵抗性前列腺癌男性恩杂鲁胺治疗5年生存预测和安全结果研究

Baidu
map
Baidu
map
Baidu
map